Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a key mediator of non-canonical Wnt signaling and plays a critical role in cancer progression. ROR1 is selectively and highly expressed in various solid tumors and hematological malignancies, while absent in normal adult tissue, making it a promising target for cancer therapy. Currently, there is a need …Read More >

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present multiple posters detailing latest scientific insights, covering a range of cutting-edge topics from preclinical tumor model development and biomarker discovery, to the evaluation of novel anti-cancer therapies. Explore this quick overview of WuXi Biology’s pioneering …Read More >

WuXi Biology offers an integrated package of preclinical cancer pharmacology services for targeted oncology and immuno-oncology.  Our platform includes in vitro cell-free and cell-based assays, a comprehensive panel of in vivo tumor models, and multidisciplinary ex vivo PD analysis services. We have pioneered the development of over 1,500 PDX models across 30 cancer types, encompassing both …Read More >

High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity.  This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy.  WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >

We offer an extensive panel of cutting-edge immune profiling and biomarker discovery services to support: Target discovery and validation Drug efficacy assessment Mechanism of action and PD studies Identification of predictive biomarkers, to support patient stratification Check out our comprehensive platform of immunology services View our panel of biomarker and immune profiling services

Multidisciplinary testing platforms that enable support to detect, develop, and validate biomarkers of cancer. End-to-end services in pathology, flow cytometry, and molecular biology techniques Rigorous quality management system, and well-established sample and data management procedures System biology analysis utilizing multidisciplinary testing platforms CAP-accredited clinical biomarker lab has been established since 2015 View our comprehensive platform …Read More >

Pilot Studies (selection of optimal time points and dosing) In vivo treatment Sample collection (from complex tissue to single cell isolation) Library preparation and sequencing Bioinformatics analysis View our cutting-edge immune profiling and biomarker platforms

Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) have emerged as key regulators of neuronal degeneration and axon growth.  WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry demonstrating the use of ligand- and structure-based drug design approaches to discover an amino-pyrazine chemical series of DLK and …Read More >

Offering a comprehensive platform of in vitro imaging-based assays to screen compounds for cancer, inflammation, and autoimmune diseases. Our services include: Imaging assays for cell proliferation and apoptosis Imaging assays for cell cycle analysis Cell-based functional assays, including: Antibody internalization Live-cell immunocytochemistry Cellular movement and morphology monitoring Assays for 3D cell models, including: Spheroid growth …Read More >